Εμφάνιση απλής εγγραφής

dc.creatorJavorac J., Živanovic D., Stojkov S., Milicic J.D., Fradelos E., Savic N.en
dc.date.accessioned2023-01-31T08:28:51Z
dc.date.available2023-01-31T08:28:51Z
dc.date.issued2021
dc.identifier10.26355/eurrev_202112_27647
dc.identifier.issn11283602
dc.identifier.urihttp://hdl.handle.net/11615/74091
dc.description.abstractOBJECTIVE: COVID-19 is associated with an increased incidence of pulmonary embolism (PE). Elevated D-dimer levels are linked to an increased risk of PE and poor clinical outcome. We reported a case of PE in a COVID-19 patient with normal D-dimer levels and conducted a review of the literature on the subject. CASE REPORT: A 38-year-old man with no prior comorbidities returned to the COVID-19 outpatient clinic 36 hours after being discharged from the hospital, where he had been treated for COVID-19 pneumonia. He reported a sudden feeling of dyspnea and chest pain. The physical examination was unremarkable. No new changes were detected on the chest X-ray. D-dimer and cardiac-specific markers values were within the referent range. The patient underwent an urgent computerized tomography pulmonary angiography which revealed signs of bilateral arterial thrombosis. He was treated with a therapeutic dose of low molecular weight heparin and discharged after 15 days, with a recommendation to use a direct oral anticoagulant. CONCLUSIONS: Healthcare professionals should be aware that PE can occur as a late complication of COVID-19. Clinical suspicion of PE should lead physicians to use additional diagnostic methods to confirm or rule out PE, even if D-dimer levels are within the referent range. © 2021 Verduci Editore s.r.l. All rights reserved.en
dc.language.isoenen
dc.sourceEuropean Review for Medical and Pharmacological Sciencesen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85123227794&doi=10.26355%2feurrev_202112_27647&partnerID=40&md5=6e5ebfa0e4d0a9d50dd90eb19d3b6613
dc.subjectacetylsalicylic aciden
dc.subjectantibiotic agenten
dc.subjectapixabanen
dc.subjectcorticosteroiden
dc.subjectD dimeren
dc.subjectlow molecular weight heparinen
dc.subjectnadroparinen
dc.subjectprednisoloneen
dc.subjectvitaminen
dc.subjectfibrin degradation producten
dc.subjectfibrin fragment Den
dc.subjectlow molecular weight heparinen
dc.subjectadulten
dc.subjectcase reporten
dc.subjectclinical articleen
dc.subjectcomputed tomography pulmonary angiographyen
dc.subjectcoronavirus disease 2019en
dc.subjectdyspneaen
dc.subjectground glass opacityen
dc.subjectheart right bundle branch blocken
dc.subjecthospital readmissionen
dc.subjecthumanen
dc.subjectlung embolismen
dc.subjectmaleen
dc.subjectoxygen therapyen
dc.subjectrespiratory failureen
dc.subjectReviewen
dc.subjectT waveen
dc.subjectthorax painen
dc.subjectthorax radiographyen
dc.subjectblooden
dc.subjectcomplicationen
dc.subjectcomputed tomographic angiographyen
dc.subjectdiagnostic imagingen
dc.subjectimmunologyen
dc.subjectincidenceen
dc.subjectisolation and purificationen
dc.subjectlungen
dc.subjectlung embolismen
dc.subjectreference valueen
dc.subjectthorax painen
dc.subjecttreatment outcomeen
dc.subjectvascularizationen
dc.subjectvirologyen
dc.subjectAdulten
dc.subjectChest Painen
dc.subjectComputed Tomography Angiographyen
dc.subjectCOVID-19en
dc.subjectFibrin Fibrinogen Degradation Productsen
dc.subjectHeparin, Low-Molecular-Weighten
dc.subjectHumansen
dc.subjectIncidenceen
dc.subjectLungen
dc.subjectMaleen
dc.subjectPulmonary Embolismen
dc.subjectReference Valuesen
dc.subjectSARS-CoV-2en
dc.subjectTreatment Outcomeen
dc.subjectVerduci Editore s.r.len
dc.titleCOVID-19 associated pulmonary embolism with D-dimer values within the referent range: A case report and review of the literatureen
dc.typeotheren


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής